• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Clinical Trials in Asia

Article

Clinical development teams are looking toward emerging markets in Asia because each has its own unique market quality.

Clinical development teams are looking more toward smaller Asian countries with emerging markets rather than India and China, according to a report by Cutting Edge Information.

According to the clinical research report, development teams typically looked into India and China because they were the two largest members of the BRIC countries. Now, Malaysia, Hong Kong, Taiwan, Thailand, Singapore, South Korea and the Philippines are being considered more often for their own unique market qualities.

"India and China opened the door for [pharmaceutical] companies to consider focusing on Asia for large parts of their clinical development strategy," says Adam Bianchi, chief operating officer at Cutting Edge Information, in a statement. "Now we see a more sophisticated breakdown of country-by-country benefits and costs. Many of our benchmark partners are champions within their companies for this change of perspective."

Asian countries are often used for clinical development because they offer the highest number of patients, the report says. They also have strong physician-patient relationships, which these companies can tap into to boost enrollment and retention for studies.

One company in the study found that the Philippines’ regulatory environment and medical infrastructure offer a solid base for clinical research. However, the report says, companies make the mistake of approaching specific emerging markets with regional strategies when they should be developing detailed plans for running trials in each market.

Another area of concern for companies tapping into the Asian emerging markets is intellectual property. According to the report, Asia has a reputation for poor intellectual property protections. Luckily, there has been progress, according to the studies.

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice